SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

STRKs sharp rally has traders focused on Starknets privacy and Bitcoin DeFi plans, alongside its STARK-based post-quantum security narrative. Bullish momentum and ecosystem optimism are tempered by concerns about token unlocks, selling pressure, and whether the move is a short-lived pump.

Bittensor is an open-source protocol that powers a decentralized, blockchain-based machine learning network. Machine learning models train collaboratively and are rewarded in TAO according to the informational value they offer the collective. TAO also grants external access, allowing users to extract information from the network while tuning its activities to their needs.  Ultimately, BitTensors vision is to create a pure market for artificial intelligence, an incentivized arena in which consumers and producers of this valuable commodity can interact in a trustless, open and transparent context.  Bittensor enables:  -A novel, optimized strategy for the development and distribution of artificial intelligence technology by leveraging the possibilities of a distributed ledger. Specifically, its facilitation of open access/ownership, decentralized governance, and the ability to harness globally-distributed resources of computing power and innovation within an incentivized framework.  -An open-source repository of machine intelligence, accessible to anyone, anywhere, thus creating the conditions for open and permission-less innovation on a global internet scale.  -Distribution of rewards and network ownership to users in direct proportion to the value they have added.

Bittensor

TAO is drawing attention amid a recent price rebound, with traders debating whether the move can continue or give way to another pullback. Bulls point to Bittensors decentralized-AI ecosystem and subnet development, while cautious voices question adoption and near-term catalysts amid broader crypto and macro uncertainty.

Zillow Group, Inc. engages in the provision of real estate and home-related information marketplaces on mobile and the web. The company was founded by Richard N. Barton and Lloyd D. Frink in December 2004 and is headquartered in Seattle, WA.

Zillow Group Inc - Ordinary Shares - Class C

Zillow Group Inc Class C

Zillows steep selloff is being tied to a weak housing markethigh mortgage rates and affordability pressures are weighing on transactionswith lowered guidance adding to concerns despite revenue growth. Bearish traders see further downside, while bulls argue the shares are oversold and point to growth in rentals, mortgages and AI-enabled products.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Attention centers on Compounds institutional-market push, including a reported launch, new leadership and investment plans, alongside anticipation for V4. Many traders are bullish on COMPs limited supply and potential breakout, while skeptics point to weak relative price action and concerns about protocol liquidity.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

ZVRA is drawing attention after a recent rise in trading activity, with traders comparing the companys Niemann-Pick franchise to IntraBios reported acquisition and arguing that Zevra may be undervalued; some speculate about a potential buyer, but no deal is confirmed. The discussion also points to the pending European re-examination and upcoming results, with views divided over regulatory prospects and the stocks gains.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEARs rally is being tied to the launch of confidential perpetual trading powered by Hyperliquid, with traders also highlighting the tokens AI-agent and cross-chain Intents narrative. The reaction is largely bullish, though some remain cautious about pullbacks and the earlier NEAR Intents exploit.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

A Brazilian federal appeals court restored Sigma Lithiums existing mining licenses, allowing operations to resume after a shutdown. Traders welcomed the restart, while noting that the plant expansion remains blocked pending a community-related survey, leaving legal and execution risks in focus.

iShares Bitcoin Trust ETF (The) - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin Trust ETF

Bitcoins rebound and consolidation are driving IBIT discussion, with many traders treating pullbacks as buying opportunities and anticipating further gains, while others warn that momentum could fade. The conversation is largely about Bitcoins direction rather than a confirmed IBIT-specific catalyst.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

Gold miners are drawing attention as traders assess whether GDXs correction is bottoming, with higher real yields and a stronger dollar cited as near-term pressure on gold and miners. Some see signs of a rebound and are buying dips, while others want confirmation and warn that the pullback may continue; longer-term bulls point to central-bank buying and concerns about debt and currency debasement.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

XCN is drawing attention amid a modest rebound and ongoing consolidation, with traders focused on chart levels, returning volume and the prospect of a breakout. Some are buying dips and expecting momentum to build, while others warn that thin volume and repeated rallies that fade make the move look like a pump-and-dump; broader crypto-market weakness is also cited.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

S&P 500, Nasdaq And Dow Close At Record Highs Amid Positive Reports Of US-Iran Ceasefire Negotiations —  IBM, SNOW, CZR, AKTX, LLY In Focus

Equity

U.S. and Iranian negotiators agreed on a 60-day memorandum of understanding to extend the ceasefire, media reports suggested.

AKTX Stock Shoots 50% Higher To Head Toward Best Month In Nearly 11 Years – What’s Fueling This Super Rally?

Akari Therapeutics’ CEO Abizer Gaslightwala highlighted the potential of the company’s proprietary platform to treat cancer ahead of ASCO 2026.

VNET Group, Akari Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

US stock futures up, VNET Group shares down 3.8% after reporting Q1 loss of $(1.20) per share on $390.133 million sales. Other stocks also fall.read more...

Why Akari Therapeutics Stock Is Falling On Tuesday?

Discover why Akari Therapeutics PLC (NASDAQ: AKTX) stock is falling on Tuesday after last week's massive 255% rally on positive preclinical cancer data.read more...

Akari Therapeutics Stock Jumps On Promising Preclinical Data

Akari Therapeutics shares are surging after preclinical data showed AKTX101 synergized with KRAS inhibition in pancreatic cancer models.read more...

This Emerging Biotech Wave Could Create the Next Monster Healthcare Winners

The biotechnology sector continues attracting speculative capital as investors aggressively position around next-generation oncology, metabolic disease, and CNS therapy platforms. Artificial intelligence, precision medicine, RNA biology, and novel drug delivery technologies are rapidly reshaping how Wall Street evaluates emerging healthcare companies. As larger pharmaceutical companies race to secure pipeline assets and differentiated platforms, smaller clinical-stage companies with compelling preclinical or clinical data are increasingly finding themselves under the spotlight. $AKTX, $NTHI, $MTVA, $HCWB, $BAC, $STT, $BCS

AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside 

Akari said its experimental therapy AKTX-101 showed strong results when paired with an already-approved cancer drug in lab tests on pancreatic cancer cells that carry a common KRAS mutation.


The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Why Akari Therapeutics Stock Is Surging On Thursday?

Akari Therapeutics PLC (NASDAQ:AKTX) sees stock growth fueled by Q1 2026 earnings optimism and a new European patent for its PH1 ADC payload.read more...

This account has been verified as an official AKTX representative.

Verified Account

Akari Therapeutics

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$8.77
Prev Close	$8.13
Open	$8.51
Dividend Yield	0.00%
50-Day Moving Average	$9.02
Beta	0.63
Avg. Volume	81,405.42
PE Ratio	-0.03

52-Week High	$39.64
52-Week Low	$3.02
Market Capitalization	$15.35M
EPS (Annual)	N/A
Price to Book	0.83
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

AKTX Fundamentals